Boundless Bio Files 8-K: Bylaws, Financials Updated
Ticker: BOLD · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1782303
| Field | Detail |
|---|---|
| Company | Boundless Bio, INC. (BOLD) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $16.00, $100.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
TL;DR
Boundless Bio filed an 8-K updating bylaws and financials.
AI Summary
On April 2, 2024, Boundless Bio, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, and other events. It also includes financial statements and exhibits. No specific dollar amounts or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates updates to Boundless Bio's corporate governance documents and financial reporting, which are standard procedures for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine corporate housekeeping and does not disclose any significant new risks or material adverse events.
Key Players & Entities
- Boundless Bio, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Diego, CA (location) — Principal Executive Offices
FAQ
What specific amendments were made to Boundless Bio's articles of incorporation or bylaws?
The provided excerpt does not detail the specific amendments made to the articles of incorporation or bylaws.
What are the key financial statements included in this 8-K filing?
The excerpt states that financial statements are included but does not specify which ones.
What is the primary purpose of this 8-K filing for Boundless Bio?
The primary purpose is to report amendments to articles of incorporation or bylaws, other events, and financial statements and exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 2, 2024.
What is Boundless Bio's principal executive office address?
Boundless Bio's principal executive office is located at 9880 Campus Point Drive, Suite 120, San Diego, CA 92121.
Filing Stats: 985 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2024-04-02 16:01:34
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share BOLD Nasdaq Global Select
- $16.00 — mon stock at a public offering price of $16.00 per share. The gross proceeds to the Co
- $100.0 m — oceeds to the Company from the IPO were $100.0 million, before deducting underwriting di
Filing Documents
- d796750d8k.htm (8-K) — 29KB
- d796750dex31.htm (EX-3.1) — 36KB
- d796750dex32.htm (EX-3.2) — 170KB
- 0001193125-24-084736.txt ( ) — 409KB
- bold-20240402.xsd (EX-101.SCH) — 3KB
- bold-20240402_lab.xml (EX-101.LAB) — 19KB
- bold-20240402_pre.xml (EX-101.PRE) — 12KB
- d796750d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Certificate of Incorporation of Boundless Bio, Inc. 3.2 Amended and Restated Bylaws of Boundless Bio, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Boundless Bio, Inc. Date: April 2, 2024 By: /s/ Jessica Oien Name: Jessica Oien Title: Chief Legal Officer and Corporate Secretary 3